arrow_back Back to App

US-Israel Health Innovation: New Medicines and Medical Technologies.

This act establishes a cooperation program between the US and Israel to develop new health products and services, such as medicines, medical devices, and telemedicine. Through this program, citizens may gain access to innovative treatments and better healthcare in the future, as well as safer and more accessible biological products.
Key points
Support for research into new medicines, vaccines, and medical technologies, potentially improving treatment access and quality.
Development of telemedicine and digital health solutions, facilitating remote access to medical care.
Strengthening the security of biological product supply chains to prevent market shortages.
Potential for new job creation in the medical technology and pharmaceutical sectors.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_4473
Sponsor: Rep. Weber, Randy K. Sr. [R-TX-14]
Process start date: 2025-07-16
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

BIRD Health Act of 2025

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_4473.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-07-16.

What are the main provisions?

Key points include:

  • Support for research into new medicines, vaccines, and medical technologies, potentially improving treatment access and quality.
  • Development of telemedicine and digital health solutions, facilitating remote access to medical care.
  • Strengthening the security of biological product supply chains to prevent market shortages.
  • Potential for new job creation in the medical technology and pharmaceutical sectors.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Weber, Randy K. Sr. [R-TX-14].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Health Public Investments Economy